2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
09/27/17MyoKardia Provides Update on MYK-491 Clinical Progress
Single Ascending Dose Trial in Healthy Volunteers Continues Enrollment in Order to Refine Exposure-Activity-Relationship; Topline Data Expected by Early 2018 Next Trial of MYK-491 in DCM Patients Expected to Initiate by Year-End SOUTH SAN FRANCISCO, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today provided a c... 
09/18/17MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting
New Positive Data on Secondary and Exploratory Endpoints Consistent with Previously Reported Topline Results SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study of mavacamten... 
08/30/17MyoKardia to Present at Two Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced its participation in the following upcoming investor conferences:  Wells Fargo Securities 2017 Healthcare Conference in Boston, MA on Wednesday, September 6, 2017 at 10:15 a.m. ET 2017 Cantor Fitzgerald Global Healthcare Conference in New... 
08/14/17MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the closing of its previously announced underwritten public offering of 4,025,000 shares of common stock, at the public offering price of $35.50 per share, which included 525,000 shares sold pursuant to the full exercise by the underw... 
08/10/17MyoKardia to Present at 2017 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, at 1:55 p.m. ET. To access the live webcast of MyoKardia’s presentation, please visit the “Events &... 
08/08/17MyoKardia Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,500,000 shares of its common stock at a public offering price of $35.50 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase an ad... 
08/07/17MyoKardia Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering of 3,500,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters ... 
08/07/17MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress
Positive Topline Results in First Patient Cohort of Phase 2 PIONEER-HCM Study Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT (5:30 a.m. PDT) SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported business highlights and financial results for the secon... 
08/07/17MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Phase 2 Study Met Primary and Key Secondary Endpoints Results from First Patient Cohort of PIONEER-HCM Accepted for Oral Presentation at Heart Failure Society of America’s 21st Annual Scientific Meeting Enrollment Complete in Second, Low-Dose Patient Cohort; Topline Data Expected Q1 2018 Company to Discuss Results on Conference Call Today at 8:30 a.m. EDT (5:30 a.m. PDT) SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) --  MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the ... 
07/31/17MyoKardia to Announce Second Quarter 2017 Financial Results and Host Conference Call on Monday, August 7, 2017
SOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report its second quarter 2017 financial and operating results before the U.S. financial markets open on Monday, August 7, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a busin... 
05/09/17MyoKardia Reports First Quarter 2017 Financial Results and Operational Progress
Company to Host Conference Call and Webcast Today at 2:00 PM PT (5:00 PM ET) SOUTH SAN FRANCISCO, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported business highlights and financial results for the first quarter ended March 31, 2017. “We are encouraged by the rapid progress we have made through MyoKardia’s multiple R&... 
05/02/17MyoKardia to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017
SOUTH SAN FRANCISCO, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report its first quarter 2017 financial and operating results after the close of the U.S. financial markets on Tuesday, May 9, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a bu... 
04/18/17MyoKardia Appoints David Meeker, M.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of David Meeker, M.D., to the Company’s board of directors. “I am thrilled to welcome David to our board at such an important time for MyoKardia,” said Tassos Gianakakos, chief executive officer. “David’s commitment to patients ... 
03/17/17MyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointments of Kim Popovits and Wendy Yarno to the Company’s board of directors. “The talent and industry knowledge of these two respected executives will be invaluable as MyoKardia navigates the next phase of growth and moves closer to a co... 
03/13/17MyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress
Topline Data from Phase 2 PIONEER-HCM Trial of MYK-461 in Symptomatic Obstructive Hypertrophic Cardiomyopathy Expected in Third Quarter of 2017               MYK-491 Dilated Cardiomyopathy Candidate Phase 1 Study of Healthy Volunteers Under Way; Topline Data Expected in Third Quarter of 2017 Sanofi Payment Received for Global Cardiomyopathy Research Collaboration Strong Cash Position to Further Advance Programs SOUTH SAN FRANCISCO, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- MyoKardia, In... 
02/28/17MyoKardia to Present at Cowen and Company 37th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, at 1:20 p.m. ET. The conference is being held March 6-8, 2017, at the Marriott Copley Place in ... 
02/02/17First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
Second Clinical Candidate Generated by MyoKardia’s Product Engine Topline Results Expected in the Third Quarter of 2017              SOUTH SAN FRANCISCO, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced dose administration for the first cohort of healthy subjects in its Phase 1 single ascending dose study of MYK-... 
02/01/17MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of June Lee, M.D., as chief operating officer, and Radhika Tripuraneni, M.D., as vice president, medical affairs. "I am thrilled to welcome these two exceptional life sciences leaders to the MyoKardia team at this pivotal time as... 
01/03/17MyoKardia Announces Advancement to Next Phase of Global Collaboration with Sanofi
Sanofi Decision to Continue Provides $45 Million Milestone to MyoKardia Collaboration has Advanced Two Novel Clinical Compounds SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, announced today that Sanofi has notified the Company that it has elected to continue the global cardiomyopathy research collaboration...